NeXT Personal holds Medicare coverage in breast and lung cancer; the thesis turns on whether volume scales fast enough to offset cash burn before runway ends

Bull

A positive outcome is full-year clinical test volume reaching 43,000–45,000 tests with clinical revenue of $10–11M, demonstrating that the sequential growth rate seen in Q1 2026 (26% quarter-over-quarter, 258% year-over-year) is sustainable across all four quarters. This would confirm that Medicare reimbursement is driving broad oncologist adoption in both breast and lung cancer surveillance, meaningfully reducing the cash burn concern and supporting the case that the business can reach self-sustaining scale on its existing $233M cash runway.

Bear

The most likely failure mode is volume growth decelerating after the initial Medicare coverage surge, as early adopters are captured but broader oncologist pull-through proves slower than guided, resulting in full-year tests falling well short of 43,000 and clinical revenue missing the $10M floor. A secondary risk is reimbursement friction — coverage-to-payment conversion issues, prior authorization burdens, or lower-than-expected average selling prices — compressing revenue per test and widening cash burn even if volume nominally grows.